Guy B, Fourage S, Hessler C, Sanchez V, Millet M J
Research Department, Pasteur Merieux Connaught, 69280 Marcy l'Etoile, France.
Clin Diagn Lab Immunol. 1998 Sep;5(5):732-6. doi: 10.1128/CDLI.5.5.732-736.1998.
Outbred OF1 mice were immunized subcutaneously with flu vaccine, either in the neck or in the lumbar region (back), in combination with adjuvants inducing either a Th1- or a Th2-type response, referred to as adjuvants A1 and A2, respectively. After two parenteral immunizations, the mice were boosted intranasally with nonadjuvanted vaccine. The serum response was analyzed after each immunization by measuring specific immunoglobulin A (IgA), IgG1, and IgG2a antibody levels, while the local response (same isotypes) was measured in the salivary glands after the mucosal boost by ELISPOTs. We observed that systemic priming at any of the two sites with a Th2 rather than a Th1 adjuvant dramatically enhanced the mucosal IgG1 and IgA responses following a mucosal boost with unadjuvanted vaccine. In addition, as judged by the IgG2a/IgG1 ratios and serum IgA levels, immunization of mice in the back induced a rise in Th2 response compared to neck immunization with adjuvant A1. In contrast, such back immunization with adjuvant A2 reversed the Th1-Th2 balance in favor of the Th1 response compared to neck immunization. Similar differences were observed in mucosal antibody levels according to the site of priming with one given adjuvant; priming in the back with adjuvant A1 increased the mucosal IgA and IgG1 responses compared to neck priming, while the local IgG2a levels were decreased. The reverse was true for adjuvant A2. Back versus neck priming with this latter adjuvant decreased the mucosal IgG1 response, while local IgG2a levels were increased. The different lymphatic drainages of the two sites of parenteral immunization may explain these differences, due to the targeting of particular lymphoid inductive sites. Some of these sites may represent crossroads between systemic and mucosal immunity.
远交群OF1小鼠分别在颈部或腰部(背部)皮下接种流感疫苗,并与诱导Th1型或Th2型反应的佐剂联合使用,分别称为佐剂A1和A2。两次肠胃外免疫后,小鼠通过鼻内接种无佐剂疫苗进行加强免疫。每次免疫后,通过测量特异性免疫球蛋白A(IgA)、IgG1和IgG2a抗体水平分析血清反应,而在黏膜加强免疫后,通过酶联免疫斑点法(ELISPOT)测量唾液腺中的局部反应(相同的同种型)。我们观察到,用Th2而非Th1佐剂在两个部位中的任何一个进行全身致敏,在用无佐剂疫苗进行黏膜加强免疫后,会显著增强黏膜IgG1和IgA反应。此外,根据IgG2a/IgG1比值和血清IgA水平判断,与用佐剂A1在颈部免疫相比,在背部免疫小鼠会诱导Th2反应增强。相反,与颈部免疫相比,用佐剂A2在背部进行这种免疫会使Th1-Th2平衡向Th1反应方向逆转。根据用一种给定佐剂进行致敏的部位,在黏膜抗体水平上也观察到了类似差异;与颈部致敏相比,用佐剂A1在背部致敏会增加黏膜IgA和IgG1反应,而局部IgG2a水平降低。佐剂A2则相反。用后一种佐剂在背部与颈部进行致敏会降低黏膜IgG1反应,而局部IgG2a水平会升高。肠胃外免疫两个部位不同的淋巴引流可能解释了这些差异,这是由于特定淋巴诱导部位的靶向作用。其中一些部位可能代表全身免疫和黏膜免疫的交叉点。